The Australian Regulatory Pathway: An Accelerated Entry into First-in-Man Clinical Trials, Upcoming Webinar Hosted by Xtalks

Share Article

Australia is home to many favourable regulatory pathways that make it a choice destination for early-phase clinical trials. More sponsors are taking advantage of the shorter timelines, attractive R&D tax incentive programs, cash rebates and high-quality clinical development that is unique to Australia. Join this free webinar to learn more about the benefits of conducting first-in-man trials in Australia.

Xtalks Life Science Webinars

The featured speakers will draw upon their experience with US biopharmaceutical companies and will discuss the strategies being followed by US biopharmaceutical companies in planning their first in human studies, which are ultimately accelerating their drug development pathway.

Over the last 20 years, Australia has grown to become a destination of choice for the conduct of early-phase clinical trials. This is partly due to the favourable Australian regulatory pathway that exists where the submission of an online Clinical Trial Notification form to the Therapeutic Goods Administration (TGA) means that from submission of documents to IRB for approval to First Patient First Dose takes an average of five weeks. Coupled with the attractive R&D tax incentive program offered by the Australian Government, this model can be used to support an Investigational New Drug (IND) or Investigational Medicinal Product Dossier (IMPD) application allowing companies to speed up their drug development process.

On Tuesday, December 10, 2019 at 4pm EST, join this live webinar to learn more and understand how the favourable regulatory pathway works in Australia. The featured speakers will draw upon their experience with US biopharmaceutical companies and will discuss the strategies being followed by US biopharmaceutical companies in planning their first in human studies, which are ultimately accelerating their drug development pathway.

The featured speakers include:

  • Cameron Johnson, CEO, Nucleus Network Pty Ltd
  • Jon Fairweather, Business Development, PCI Pharma Services
  • Stewart Walker, VP, Business Development North America, CoSec

This webinar will include a live Q&A session with the speakers.

For more information or to register for this event, visit The Australian Regulatory Pathway: An Accelerated Entry into First-in-Man Clinical Trials.

ABOUT XTALKS

Xtalks, powered by Honeycomb Worldwide Inc., is a leading provider of educational webinars to the global life science, food and medical device community. Every year thousands of industry practitioners (from life science, food and medical device companies, private & academic research institutions, healthcare centers, etc.) turn to Xtalks for access to quality content. Xtalks helps Life Science professionals stay current with industry developments, trends and regulations. Xtalks webinars also provide perspectives on key issues from top industry thought leaders and service providers.

To learn more about Xtalks visit http://xtalks.com
For information about hosting a webinar visit http://xtalks.com/why-host-a-webinar/

Share article on social media or email:

View article via:

Pdf Print

Contact Author

Candice Tang
Xtalks
1 (416) 977-6555
Email >
Visit website